3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
2
Breast Diseases
2
Luminal B/HER2-negative Breast Cancer
1
Hormone Receptor Positive Breast Carcinoma
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms, Male
1
Breast Cancer Female
1
Arthralgia
1
Advanced Breast Cancer
1
Interventions
bicalutamide
4
pembrolizumab
1
nilutamide
1
exemestane
1
darolutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bulbo-Spinal Atrophy, X-Linked
×
Aromatase Inhibitors
×
Clear all
NCT02910050
2017-12-22
BETTER
Sun Yat-sen University
Phase 2
Unknown
58 enrolled